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γ-aminobutyric acid type A receptors (GABAARs) are the major mediators of synaptic
inhibition in the brain. Aberrant GABAAR activity or regulation is observed in various
neurodevelopmental disorders, neurodegenerative diseases and mental illnesses,
including epilepsy, Alzheimer’s and schizophrenia. Benzodiazepines, anesthetics and
other pharmaceutics targeting these receptors find broad clinical use, but their
inherent lack of receptor subtype specificity causes unavoidable side effects, raising
a need for new or adjuvant medications. In this review article, we introduce a new
strategy to modulate GABAeric signaling: targeting the intracellular protein interactors
of GABAARs. Of special interest are scaffolding, anchoring and supporting proteins
that display high GABAAR subtype specificity. Recent efforts to target gephyrin, the
major intracellular integrator of GABAergic signaling, confirm that GABAAR-associated
proteins can be successfully targeted through diverse molecules, including recombinant
proteins, intrabodies, peptide-based probes and small molecules. Small-molecule
artemisinins and peptides derived from endogenous interactors, that specifically target
the universal receptor binding site of gephyrin, acutely affect synaptic GABAAR numbers
and clustering, modifying neuronal transmission. Interference with GABAAR trafficking
provides another way to modulate inhibitory signaling. Peptides blocking the binding site
of GABAAR to AP2 increase the surface concentration of GABAAR clusters and enhance
GABAergic signaling. Engineering of gephyrin binding peptides delivered superior means
to interrogate neuronal structure and function. Fluorescent peptides, designed from
gephyrin binders, enable live neuronal staining and visualization of gephyrin in the
post synaptic sites with submicron resolution. We anticipate that in the future, novel
fluorescent probes, with improved size and binding efficiency, may find wide application
in super resolution microscopy studies, enlightening the nanoscale architecture of the
inhibitory synapse. Broader studies on GABAAR accessory proteins and the identification
of the exact molecular binding interfaces and affinities will advance the development of
novel GABAAR modulators and following in vivo studies will reveal their clinical potential
as adjuvant or stand-alone drugs.
Keywords: GABAA receptors, gephyrin, collybistin, protein-protein interaction (PPI), super resolution microscopy,
fluorescent probes, dimeric peptide, peptide inhibitor design
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INTRODUCTION
γ-aminobutyric acid type A receptors (GABAARs) are the
principal mediators of phasic and tonic inhibition in the
human brain, being a vital part of the molecular machinery
that creates cognition, behavior, and consciousness (Fritschy
and Panzanelli, 2014). Dysfunctional GABAARs are involved
in the pathogenesis of neurodevelopmental disorders (Ali
Rodriguez et al., 2018), schizophrenia (de Jonge et al.,
2017), postpartum depression (Mody, 2019), epilepsy
(Palma et al., 2017; Hines et al., 2018), Alzheimer’s disease
(Govindpani et al., 2017), autism (Vien et al., 2015) and
stroke (Darmani et al., 2016; Wang et al., 2018). Structurally,
these receptors belong to the pentameric ligand-gated ion
channels harboring an extracellular domain (ECD), followed
by four helical transmembrane domains (TMDs) and loops
connecting these helices. GABAARs display a highly subtype-
specific cellular and sub-cellular distribution and exhibit
distinct physiological properties, making them very attractive
pharmaceutical targets.
First GABAAR targeting compounds have been discovered
more than a century ago. In 1904, Bayer marketed barbital,
the first barbiturate and positive allosteric modulator of
GABAARs (Löscher and Rogawski, 2012). In the 1960s,
benzodiazepines, a new class of GABAAR allosteric modulators
(Sancar and Czajkowski, 2011), became commercially
available. Today, modulators of GABAAR activity find
broad clinical use as anesthetics (Propofol; Olsen, 2018),
anticonvulsants (Gabapentin) or as hypnotics, muscle-
relaxants and anxiolytics (Clonazepam, Diazepam), and
new experimental medicines are developed. Nonetheless,
wider application of these classical GABAAR modulators
is limited by their lack of receptor subtype specificity, due
to the fundamental structural and functional constraints:
pharmacologically exploited sites are small hydrophobic
pockets with high subunit sequence homology located at
the folded ECDs and TMDs of the ion channels (Figure 1;
Miller et al., 2017; Kasaragod and Schindelin, 2018; Masiulis
et al., 2019). Additionally, binding sites on the interface
between two subunits, such as the benzodiazepine binding
site, are shared among different synaptic receptor subtypes.
Consequently, the action of classical clinically relevant
GABAAR ligands can be unspecific and provoke unavoidable
side effects.
Molecules modulating receptor signaling through accessory
proteins in the central nervous system (CNS; Figure 1) emerged
as a new class of pharmaceuticals with superior receptor
specificity and potential to treat epilepsy, neuropathic pain,
fibromyalgia, migraines, and other diseases (Maher et al., 2017).
Therefore, targeting GABAAR-associated proteins might be a
superior pharmacological strategy compared to the classical
approaches. This rational approach, however, requires detailed
knowledge and advanced understanding of the intracellular
signaling of distinct GABAAR subtypes. The large number
of post-synaptic candidate proteins that directly or indirectly
associate with GABAARs is still increasing (Krueger-Burg
et al., 2017), with functional studies exploring some of their
physiological roles and organization (Uezu et al., 2016; Lu et al.,
2017), yet, the specific molecular details of these interactions
remain largely unknown. We hypothesize that the identification
of the exact molecular binding interfaces and binding affinities
of known and newly identified GABAAR associated proteins
will not only greatly expand our basic understanding of CNS




The majority of GABAARs assemble as heteropentamers to form
GABA-gated chloride channels. Different subunit combinations
possess unique pharmacology (Olsen and Sieghart, 2009),
divergent brain region distribution (Wisden and Seeburg, 1992),
cell-type specific expression (Lee and Maguire, 2014), and
varying subcellular localization between synaptic and extra-
synaptic sites (Mody and Pearce, 2004). Thus, subtype-specific
modulators of GABAAR signaling should affect distinct circuits,
brain regions or subcellular populations with improved accuracy
and more selective pharmacology. Combined structural and
functional studies have revealed the molecular details of the
interplay of the ECD and TMDs in channel gating (Miller
and Aricescu, 2014; Lu et al., 2017; Kasaragod and Schindelin,
2018; Zhu et al., 2018; Laverty et al., 2019). Structural
studies of the receptors could, so far, not resolve most of
the presumably intrinsically disordered intracellular regions of
GABAARs. Short intracellular receptor regions, however, do
adopt defined conformations when engaged with structured
intracellular interactors, such as gephyrin (Maric et al., 2014) and
the AP2 complex (Kittler et al., 2008; Table 1). Functional studies
validated that distinct motifs within these unstructured regions
exert tight control over channel biosynthesis, recycling, diffusion
and synaptic recruitment (Tretter et al., 2012; Nakamura et al.,
2015; Groeneweg et al., 2018; Lorenz-Guertin and Jacob, 2018).
Remarkably, these intracellular regions display the highest level
of sequence heterogeneity among receptor subunits, thereby
enabling subtype-specific modulation of GABAergic signaling.
Agents targeting these discrete regions will probably be highly
selective and could affect GABAAR subtypes with distinct
functional and pharmacological properties. It is noteworthy that,
so far, all intracellular GABAAR interactions that displayed
sufficient affinity and specificity ended up being exploited to




The concept of neurotransmission modulation through targeting
receptor-scaffolding protein interactions originated from studies
investigating PSD-95/Discs-large/ZO-1 (PDZ) domain carrying
proteins. These showed that through modulation of receptor-
scaffolding protein interactions a variety of responses could be
achieved, ranging from disruption of glutamate signaling to
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FIGURE 1 | Schematic representation of a γ-aminobutyric acid type A receptors (GABAARs) and sites for pharmaceutical intervention. Orthosteric and allosteric
agonists and antagonist are classical activity modulators that bind directly to the extracellular domain (ECD) or, in case of lipids and neurosteroids to the
transmembrane domain (TMD) of GABAARs. Each of the sites could occur in five subunits or at five interfaces, or only in distinct subunits and specific interfaces.
Channel blockers bind within the ion pore formed by the GABAAR pentamer. Intracellular interactors such as Collybistin (CB; Hines et al., 2018) and gephyrin (Maric
et al., 2014) interact with distinct intracellular regions of a subset of GABAAR subunits. Transmembrane interactors such as LHFPL4 interact with the TMDs of
γ2 subunit containing GABAARs (Davenport et al., 2017; Yamasaki et al., 2017). Cartoon representation of structurally characterized and predicted scaffold-GABAAR
complexes. CB is shown in gray in its extended conformation (PDB-ID 4mt7) with its SH3 domain (PDB-ID 4mt6; Soykan et al., 2014) binding to a fragment of the
GABAAR α2 subunit (Hines et al., 2018). Peptide backbones of resolved SH3 domain ligands (PDB-IDs 2df6, 4hvu, 4hvv, 4hvw, 4j9f, 4ln2 and 4rtz) are
superimposed to indicate the putative GABAAR α2 binding site. The radixin FERM domain is shown in gray. Peptide backbones of resolved radixin FERM domain
ligands (PDB-IDs 1j19, 2ems, 2d2q) are superimposed to indicate the putative GABAAR α5 binding site. Cartoon representation of the gephyrin E domain in complex
with short linear GABAAR (PDB-IDs 4tk1, 4tk2, 4tk3, 4tk4) and GlyR derived peptides (PDB-IDs 2fts, 4u90, 4u91).
neuroprotective effects in ischemic brain damage (Hammond
et al., 2006; Sainlos et al., 2011; Bach et al., 2012; Figure 2A).
These results suggested that modulation of the inhibitory
neurotransmission could be accomplished in a similar way, a
concept recently proved with the inhibitory scaffold protein
gephyrin (Maric et al., 2017).
Scaffolding proteins, such as gephyrin (Specht et al.,
2013), radixin (Loebrich et al., 2006; Hausrat et al., 2015)
and (collybistin, CB; Mayer et al., 2013; Hines et al.,
2018), dynamically regulate the cell membrane distribution of
postsynaptic and extrasynaptic GABAARs. Interestingly, their
scaffolding functions are highly receptor specific, potentially
allowing a fine tuning of neurotransmission.
Radixin
Radixin is involved in the anchoring of numerous membrane
proteins to the actin cytoskeleton (Kawaguchi et al., 2017). Its
C-terminal domain mediates actin binding, while the N-terminal
FERM domain functions as a universal protein-binding module
that directly interacts with receptors, extracellular matrix
components, transmembrane and adhesion proteins (Kitano
et al., 2006; Takai et al., 2007; Terawaki et al., 2007, 2008;
Yogesha et al., 2011; Figure 1). Radixin also harbors a central
α-helical domain, which either adopts a closed or elongated
conformation to allow its auto-inhibitory module to mask
the FERM domain. In neurons, radixin is activated through
phosphorylation, which enables its simultaneous binding to
cytoskeletal elements and transmembrane proteins, including
α5 subunit containing GABAARs (Loebrich et al., 2006; Hausrat
et al., 2015). In primary hippocampal neuronal cultures,
the association of radixin with α5-containing GABAARs at
extrasynaptic sites decreases upon maturation, in contrast,
the number of α5-containing GABAARs, that associate with
gephyrin at post-synaptic sites remains constant (Brady and
Jacob, 2015). Structural and thermodynamic details of the
radixin-GABAAR α5 complex will reveal whether modulation
can be achieved without simultaneously affecting the binding of
other ligands.
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Collybistin (CB) is a guanine nucleotide exchange factor for
Cdc42, a gephyrin binding partner (Kins et al., 2000) and an
important determinant of inhibitory postsynaptic membrane
formation and plasticity (Harvey et al., 2004; Tyagarajan et al.,
2011a). Robust evidence supports the role of CB in GABAAR
scaffolding with yeast three-hybrid studies (Saiepour et al., 2010)
and proteomic studies (Nakamura et al., 2016) suggesting the
presence of a tripartite complex between gephyrin, CB and
α2 subunit containing GABAARs. Recently, a thermodynamic
analysis revealed that CB binds GABAAR α2-subunits with
high selectivity and affinity (Hines et al., 2018; Figure 1 and
Table 1). CB is targeted to the neuronal surface membrane
through phosphoinositides (Reddy-Alla et al., 2010; Ludolphs
et al., 2016) and interfering human mutations result in cognitive
deficits (Long et al., 2016; Chiou et al., 2019). Deficiency in
CB reduces gephyrin and GABAAR clustering and impairs
spatial learning (Papadopoulos et al., 2007, 2008). Moreover,
mice with a mutation in the α2-subunit binding region of CB
display a loss of a distinct subset of inhibitory synapses and
a decreased amplitude of inhibitory synaptic currents, which
results in a phenotype with increased susceptibility to seizures
and early mortality (Hines et al., 2018). Notably, treatment with
the α2/α3-selective positive modulator AZD7325 improves the
conditions of affectedmice, suggesting that compounds targeting
the CB-GABAAR α2 complex could provide an alternative route
to specifically affect GABAARs containing the α2 subunit.
Neuroligin 2
Proteomic studies (Kang et al., 2014; Nakamura et al., 2016)
revealed that the synapse-specific adhesion molecule neuroligin
2 (NL2; Varoqueaux et al., 2004) strongly associates with a
subset of GABAAR subtypes and GABAAR scaffolds. Neuroligin
dysfunction has been implicated in autism (Pettem et al.,
2013) and specific intracellular residues in NL1 (Nguyen
et al., 2016; Letellier et al., 2018) and NL2 (Poulopoulos
et al., 2009; Kang et al., 2014) are critical for proper
GABAergic signaling. Yet, the exact molecular interfaces, that
mediate the direct or indirect gephyrin or CB dependent
(Soykan et al., 2014) interactions of neuroligin with GABAAR,
remain uncharacterized. These molecular insights could greatly
contribute to our understanding of the development of the
inhibitory synapse, as well as the underlying molecular causes
of developmental diseases. Neuroligin family members exert
distinct roles in the formation and stabilization of inhibitory
and excitatory synapses and display distinct cellular and
subcellular distributions. Accordingly, molecules that interfere
with their isoform-specific interactions could act as highly
cell-type selective modulators of neurotransmission.
Gephyrin
Gephyrin is a prime candidate for the role of master regulator of
neuronal function at inhibitory sites (Tyagarajan and Fritschy,
2014) and specifically the GABAergic synapses (Choii and
Ko, 2015). Initially identified as a glycine receptor binding
(Pfeiffer et al., 1982) and scaffolding protein (Feng et al.,
1998), gephyrin was later found to be responsible for the
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FIGURE 2 | Structure of representative inhibitors and labels of the inhibitory post-synaptic scaffold gephyrin and the excitatory post-synaptic scaffold PSD-95.
(A) Peptidomimetic and dimeric PSD-95/Discs-large/ZO-1 (PDZ) domain binders. PSD-95 binding peptides (green) were dimerized and combined with
cell-penetrating moieties (violet). (1) Peptidomimetic ligand for a α-1 syntrophin PDZ domain (Hammond et al., 2006). (2) Peptidomimetic inhibitor of the PSD-95
PDZ2 domain (Bach et al., 2011) (3) Dimeric inhibitor of PSD-95 PDZ domains, showed strong inhibition of AMPA receptor synaptic currents (Sainlos et al., 2011).
(4) Dimeric inhibitor of PSD-95 PDZ domains, showed neuroprotective properties in mice with cerebral ischemia (Bach et al., 2012). (B) Engineered peptide-based
gephyrin inhibitors and fluorescent labels. (5) Peptide-based fluorescent gephyrin label (Maric et al., 2017). Tamra dye was directly conjugated to gephyrin binding
sequence (blue) combined with cell penetrating peptide (in purple). (6–9) Nanomolar affinity dimerized gephyrin peptide binders (blue; Maric et al., 2015). (10) The
small molecule inhibitor artemisinin competes with the universal engineered peptide-based molecules for receptor binding pocket (Kasaragod et al., 2019).
(C) Representative crystal structure of a peptide dimer engaging with a gephyrin E domain dimer (PDB-ID 4U90; Maric et al., 2015).
post-synaptic accumulation of GABAARs. The loss of gephyrin
clusters following the loss of the GABAAR γ2 subunit (Essrich
et al., 1998) and the loss of GABAAR clusters upon gephyrin
deficiency (Kneussel et al., 1999) substantiates their critical
mutual dependency. Direct binding of gephyrin to α and β
GABAAR subunits could be confirmed (Tretter et al., 2008, 2011;
Maric et al., 2011; Mukherjee et al., 2011; Kowalczyk et al., 2013;
Brady and Jacob, 2015), but the exact binding interfaces and
affinities are still largely undefined. Structural, thermodynamic
and high-end microscopic approaches elucidated the complex
structure-function relationships between gephyrin and a distinct
subgroup of inhibitory neurotransmitter receptors (Kasaragod
and Schindelin, 2018) and indicated an important role of
the nanoscale arrangement of gephyrin and the associated
receptors at post-synaptic sites (Groeneweg et al., 2018; Specht,
2019). Further functional and in-silico studies (Pennacchietti
et al., 2017) confirmed that gephyrin organizes the receptors in
distinct nanoscale structures, which shape GABAergic synaptic
potentiation and reduce current variability. The stability,
oligomerization and receptor binding of gephyrin are highly
regulated and exert tight control over receptor numbers at
post-synaptic sites, affecting synaptic strength (Alvarez, 2017;
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Groeneweg et al., 2018). Biophysical (Maric et al., 2011) and
structural (Maric et al., 2014, 2015) studies provided first
insights into the structure and function of the gephyrin-GABAAR
complexes and demonstrated that at least the GABAAR α1–3 and
GlyR β subunits bind to an overlapping site within gephyrin in
a mutually exclusive fashion (Maric et al., 2011, 2014; Figure 1
and Table 1). Microscopy studies substantiated that gephyrin
acts as a dynamic post-synaptic platform for both, GABAARs
and GlyRs (Specht et al., 2013), and that receptor residence
times at the postsynapse depend on binding affinities and
distinct post-translational modifications (Mukherjee et al., 2011;
Specht et al., 2011). The concept of ligand competition for
gephyrin binding, therefore, lends an elegant explanation for the
comparably high diffusion dynamics of high-affinity gephyrin
binding receptors. This phenomenonmay be the natural solution
to the biological requirement to maintain distinct subsets of
receptor subtypes in high density at post-synaptic sites, while
at the same time allowing for the rapid exchange of these
receptors and scalability through diffusion dynamics (Specht,
2019). This model is also consistent with the observation of
reciprocal stabilization of receptors, and the underlying protein
scaffold, at inhibitory synapses (Essrich et al., 1998).
Gephyrin itself is dynamically regulated, affecting GABAAR
diffusion and contributing to input-specific adaptations at
postsynaptic sites (Chen et al., 2012; Villa et al., 2016; Battaglia
et al., 2018). Gephyrin phosphorylation at Ser268 and Ser270,
located in the intrinsically disordered central region of the
protein, directly affects GABAergic signaling (Tyagarajan et al.,
2011b, 2013) and induce gephyrin-mediated remodeling of
GABAergic synapses in specific neuronal cell-types (Flores
et al., 2015). Despite its major functional relevance only a
few of the molecular interfaces that engage with the central
region of gephyrin could be identified (Groeneweg et al.,
2018). The underlying molecular mechanisms for these gephyrin
phosphorylation-induced GABAAR synapse dynamics remain
to be explored in a comprehensive approach that includes an
extensive alternative splicing and complex post-translational
modification patterns of this region. Identification of the targeted
binding pockets and insights into the binding affinities of the
modified and unmodified peptide regions within the central
region of gephyrin could shed light on the enigmatic molecular
mechanisms of gephyrin multimerization, degradation and the
tuning of its ligand binding affinities. Additionally, gephyrin
isoforms are tissue-specific (Paarmann et al., 2006), therefore,
molecules targeting distinct gephyrin splice variants may display
pronounced effects in distinct tissues or brain regions.
TARGETING THE GEPHYRIN-GABAAR
COMPLEX
Gephyrin’s crucial role in glycinergic and GABAergic
transmission made it a major pharmacological target. The
modulation of synaptic responses via gephyrin was achieved
more than a decade ago using intrabodies (Zacchi et al., 2008),
and a related approach turned out to be useful for acutely
removing inhibitory synapses (Gross et al., 2016). Since then,
several studies made an impressive progress in the development
of agents affecting the intracellular interplay of GABAARs.
One such example is artemisinins [Figure 2B(10)]. Li et al.
(2017) found that artemisinins, lactones derived from the
Qinghao plant, affect pancreatic cells by binding gephyrin and
modifying GABAAR signaling. Kasaragod et al. (2019) identified
the artemisinin binding site within gephyrin and showed that
application of artemisinins reduces gephyrin and GABAARs
clustering, making artemisinins the first small molecule lead
compounds for a new class of inhibitory neurotransmission
modulators. Strikingly, the druggable artemisinin-binding
pocket overlaps with the universal receptor binding region of
gephyrin, which is critical for the interaction with GABAA and
glycine receptors (Kasaragod et al., 2019). Thermodynamic
and structural studies (Maric et al., 2011, 2014) identified the
‘‘hotspot’’ fragments of GABAA and glycine receptors that
bind to gephyrin. Biomimetic optimization of the ‘‘hotspots’’
amino acid sequence, enhanced the affinity of the resulting
peptide ligands 46,000-fold compared to the corresponding
native peptides (Maric et al., 2015, 2017; Figures 2B,C). Further
in vitro applications of these new super binder peptide reduced
GABAAR α2 conductivity and clustering, providing evidence
that GABAAR-associated proteins can be successfully targeted
with modified peptides to modulate fast synaptic inhibition
(Maric et al., 2017).
TARGETING NON-SCAFFOLD GABAAR
ASSOCIATED PROTEINS
GABAAR trafficking is pivotal for the plasticity (Luscher et al.,
2011) and the development (Lorenz-Guertin and Jacob, 2018) of
inhibitory synapses, consequently, dysfunction of the GABAAR
cycling is involved in various neurological disorders (Smith and
Kittler, 2010; Mele et al., 2019). Noteworthy, phosphorylation
of the intracellular GABAAR sites, that are involved in the
trafficking of the receptors, has been identified to control
receptor numbers and their concentration at synaptic sites
(Comenencia-Ortiz et al., 2014; Nakamura et al., 2015), a
mechanism that proves to be critical for the physiological
function of inhibitory synapses (Vien et al., 2015). Therefore,
targeting protein-protein interactions (PPIs) that mediate
GABAAR trafficking, endocytosis, degradation or recycling, is a
promising pharmacological strategy. The proposed direct protein
interactors are numerous, among them are muskelin (Heisler
et al., 2011), GABARAP (Wang et al., 1999), the brefeldin-A
inhibited GDP/GTP exchange factor 2 (Charych et al., 2004),
phospholipase C-related catalytically inactive proteins 1 and
2 (Mizokami et al., 2007), N-ethylmaleimide sensitive factor
(Goto et al., 2005), neurobeachin (Nair et al., 2013), Huntingtin-
associated protein 1, calcium-modulating cyclophilin ligand
(Kittler et al., 2004; Yuan et al., 2008) and the clathrin adaptor
protein AP2 (Kittler et al., 2005).
The AP2-GABAAR interaction rapidly modulates synaptic
GABAAR numbers, inhibitory synaptic strength, neuronal
excitability, and notably, affects animal behavior (Kittler et al.,
2000, 2005, 2008; Tretter et al., 2009). The µ2 subunit of
the clathrin adaptor protein AP2 binds with high affinity
to linear and short peptide motifs within the intracellular
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regions of specific GABAAR subunits (Table 1). Short GABAAR
derived peptides, that effectively compete with AP2 binding,
were successfully used to block the receptor internalization
in hippocampal neurons, increasing surface concentration of
GABAAR clusters by 50% (Smith et al., 2012) and enhancing
the strength of inhibitory synapses (Kittler et al., 2008).
AP2 antagonists demonstrate that the modulation of GABAAR
interactions with its intracellular trafficking partners is an
alternative way to influence GABAergic signaling.
PERSPECTIVES
Ongoing research uncovered original, seemingly contrasting,
strategies of GABAergic signaling modulation. On the one
hand, ligands disrupting gephyrin-GABAAR clustering, like
artemisinins or ‘‘super binding peptides,’’ could reduce
the GABAAR synaptic concentration and function. On the
other hand, peptides hampering receptor interaction with
AP2 trafficking protein increased the synaptic receptor levels.
In theory, these approaches could be applied together to achieve
bi-directional modulation of inhibitory neurotransmission,
promoting a shift in the dynamic equilibrium from phasic to
tonic neuronal response.
Those new strategies of GABAergic neurotransmission
modulation possess an untapped clinical potential. Agents
targeting GABAAR associated scaffold or trafficking proteins
could be applied wherever abnormal GABAergic activity or
regulation is involved in pathogenesis. In status epilepticus
patients develop a time-dependent pharmacoresistance to
GABAergic agents, probably, due to GABAAR internalization
(Naylor et al., 2005). In benzodiazepine tolerance linked to
prolonged benzodiazepine use, neurons continuously exposed
to diazepam lose postsynaptic GABAARs (Nicholson et al.,
2018). Both pathologies are related to the reduction of available
postsynaptic GABAARs and both could potentially be alleviated
by targeting GABAAR-associated proteins. Stabilization of the
gephyrin-receptor scaffolds at inhibitory postsynapses with
molecules that mimic the stabilizing action of CB (Saiepour et al.,
2010) could help prevent GABAAR loss and preserve inhibitory
neurotransmission, alternatively, applying AP2 inhibitors could
reduce GABAAR internalization and reverse the loss of
postsynaptic GABAARs. Those examples illustrate the potential
of GABAergic modulators as adjuvants ameliorating the effect
of existing potent drugs, whereas in epilepsy or other diseases
involving deregulation of inhibitory neurotransmission they
could be applied as stand-alone therapeutics.
We expect that the study of GABAAR intracellular
interactors, accelerated by in-silico predictions and high
throughput approaches, will lead to the discovery of novel
GABAergic modulators. Affinity, selectivity, bioavailability
and immunogenicity of these compounds would have to be
optimized for clinical applications, where peptide-based ligands
could be further evolved by the introduction of unnatural amino
acids, cyclization and other chemical modifications.
Microscopy is an additional intriguing application of
these molecules. The enhanced affinity and specificity of the
engineered peptide-based compounds allowed to pioneer their
use as fluorescent probes [Figure 2B(5)], enabling live neuronal
staining and visualization of inhibitory post synaptic sites with
submicron resolution (Maric et al., 2017). Compact fluorescent
peptides, developed from these super binding peptides, bring
several advantages over conventional staining agents, namely the
antibodies. In contrast to antibodies, peptide probes are live cell
compatible and could provide better resolution and localization
precision, since the fluorophore, owing to its small size, stays
close to the target surface, reducing the linkage error. Moreover,
highly affine and selective peptides could achieve stoichiometric
labeling, enabling quantification of the target protein.
Here, we discussed how the targeting of GABAAR associated
proteins could prove to be a versatile pharmacological strategy
with clinical potential. Further, we suggested that when
combined with state-of-the-art super-resolution microscopy
methods, the peptide-based fluorescent probes may resolve the
nanoscale architecture of synapses in unprecedented detail. We
anticipate that the discovery of additional GABAAR interactors
could open the way for the development of new imaging tools
and alternative pharmacological approaches.
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